Stage III Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 2 Trials for Talimogene laherparepvec (DB13896)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0091046 (Stage III Cutaneous Melanoma AJCC v7) | Active Not Recruiting | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02965716 | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | Treatment |